Theriva Biologics (TOVX) has provided an announcement.
Theriva Biologics, Inc. has received Rare Pediatric Drug Designation from the FDA for its leading drug candidate, VCN-01, targeting the treatment of retinoblastoma, a type of eye cancer in children. This follows a previous orphan drug designation for the same treatment, underscoring the importance and potential of VCN-01. Additionally, the company announced a conversion of its Series C Convertible Preferred Stock into common shares, reflecting ongoing financial developments within the company.
Learn more about TOVX stock on TipRanks’ Stock Analysis page.
